Earnings Insights · ALNY · Q3 FY2026

Alnylam Q3 2026 Earnings: AMVUTTRA Drives 52% Product Growth, but Demand Conversion and Access Risks Remain

By AlgovestIQ ResearchPublished

Share

Read Alnylam Pharmaceuticals’s results announcement (Form 8-K, filed Oct 29, 2026)

Key earnings findings

Alnylam Pharmaceuticals (ALNY) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Alnylam Pharmaceuticals reported Q3 FY2026 revenue of $1.46B against the $1.43B analyst estimate, a 1.9% beat, and EPS of $16.26 against the $1.66 analyst estimate.
  2. Management now expects full-year TTR revenue to land at the low end of the $4.2B to $4.5B range.
  3. ALNY closed at $174.00 on Oct 29, 2026, down 25.1% from $232.40 on Oct 28, 2026, the last close before the results were released.

Sources: Alnylam Pharmaceuticals results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Alnylam Pharmaceuticals beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$1.46B
$1.43B
+1.9%
EPS
$16.26
$1.66
—
  • Revenue surprise across the last 8 reported quarters has ranged from -4.5% to 30.2%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Alnylam Pharmaceuticals reported Q3 2026 total revenue of $1.46B, up 17% year over year, while net product revenue rose 52% to $1.29B on continued AMVUTTRA adoption in transthyretin amyloidosis. GAAP diluted EPS was $15.72, although the result was dominated by a $1.9B non-cash tax benefit; non-GAAP diluted EPS was $16.26.

The central issue was not the reported growth rate, but the quality and durability of TTR demand. AMVUTTRA remains a rapidly expanding product, yet management acknowledged that its expanded commercial field force has not converted higher physician engagement into patient starts as quickly as expected. The company reiterated 2026 guidance, but now expects TTR revenue to land at the low end of its range and sees Q4 headwinds from inventory normalization, pricing adjustments, potential 340B-related ordering volatility, and a more restrictive UnitedHealth Medicare Advantage policy.

Earnings Snapshot

MetricReportedChange
Total revenue$1.46B+17% YoY
Net product revenue$1.29B+52% YoY
Total TTR net product revenue$1.15B+59% YoY
AMVUTTRA net product revenue$1.13B+65% YoY
ONPATTRO net product revenue$19.6M-50% YoY
Total Rare net product revenue$142.0M+12% YoY
GIVLAARI net product revenue$89.5M+21% YoY
OXLUMO net product revenue$52.5M-1% YoY
Collaboration revenue$71.5M-80% YoY
Royalty revenue$94.7M+105% YoY
GAAP operating income$345.8M-6% YoY
Non-GAAP operating income$424.9M-11% YoY
GAAP net income$2.17BGreater than 500% YoY
GAAP diluted EPS$15.72Greater than 500% YoY
Non-GAAP net income$2.24B+412% YoY
Non-GAAP diluted EPS$16.26+410% YoY
Cash, cash equivalents and marketable securities$3.6BUp from $2.9B at year-end 2025

The Bigger Story

Alnylam’s investment case remains increasingly concentrated around the commercial execution of AMVUTTRA in ATTR cardiomyopathy. The product generated $1.13B in quarterly revenue, up 65% from a year earlier, and accounted for nearly 88% of total product revenue.

The company’s TTR franchise produced $1.15B in revenue, up 59%, as AMVUTTRA more than offset ONPATTRO’s expected decline. That growth confirms substantial market adoption following AMVUTTRA’s ATTR-CM launch, but management’s commentary also made clear that the next phase of expansion will be harder. Alnylam is attempting to broaden use beyond early-adopting specialists and experienced prescribers, where operational hurdles such as reimbursement, site-of-care coordination, and prior authorizations can slow new patient starts.

Management said AMVUTTRA had reached more than 2,000 unique U.S. prescribers since launch and represented about 24% of total TTR category prescriptions through the end of Q3. Its share of new-to-brand prescriptions remained above 30%. However, only about one-third of active category prescribers have used AMVUTTRA, leaving a sizeable opportunity but also highlighting the commercial work still required to translate physician engagement into durable demand.

Revenue and Operating Performance

Net product revenue increased 52% year over year to $1.29B and 10% sequentially. The growth was overwhelmingly driven by AMVUTTRA, particularly in U.S. ATTR-CM patients.

AMVUTTRA revenue rose to $1.13B from $685.3M a year earlier. Total TTR revenue, which includes AMVUTTRA and ONPATTRO, increased 12% sequentially. U.S. TTR revenue increased by approximately $99M from Q2, including an $81M rise in demand, a $17M inventory benefit, and modestly higher net pricing. The reported pricing result also included approximately $10M of favorable one-time gross-to-net adjustments.

Those inventory and gross-to-net items helped Q3 reported revenue but do not represent underlying demand. Management expects both inventory and net price to become headwinds to reported U.S. TTR growth in Q4.

International TTR revenue increased $20M sequentially, supported by ongoing ATTR-CM launches in Japan, Germany, and Italy, as well as ordering timing in partner markets. Management said international growth was partly offset by launch-related price reductions in certain markets.

The rare disease portfolio provided a secondary growth contribution. GIVLAARI revenue rose 21% to $89.5M, driven by more treated patients. OXLUMO revenue was essentially flat at $52.5M. Together, the products generated $142.0M, up 12%.

Total revenue grew more slowly than product revenue because collaboration revenue declined 80% to $71.5M. The comparison reflects a $300M Roche milestone recognized in Q3 2025 when the first patient was dosed in the ZENITH Phase 3 study of zilebesiran. Royalty revenue more than doubled to $94.7M, driven by higher sales of Leqvio by Novartis.

Profitability and Margins

Alnylam remained profitable on both a GAAP and non-GAAP basis, but operating income declined because the prior-year period included the large Roche milestone.

GAAP operating income fell 6% to $345.8M, while non-GAAP operating income declined 11% to $424.9M. Product gross margin was 72%, down five percentage points from the prior year. Cost of goods sold increased to 28.0% of product revenue from 23.2%, primarily because AMVUTTRA’s growing sales volume increased the blended royalty rate payable on the product.

Operating spending continued to rise as Alnylam funds both commercial expansion and late-stage development. Non-GAAP R&D expense increased 21% to $375.7M, reflecting spending on the ZENITH trial for zilebesiran and the TRITON-CM and TRITON-PN trials for nucresiran. Non-GAAP SG&A increased 13% to $295.7M, largely due to AMVUTTRA launch investments in the U.S. and key international markets.

GAAP net income of $2.17B and GAAP diluted EPS of $15.72 were not representative of the underlying quarterly operating result. The company recorded a $1.87B income-tax benefit, primarily from releasing valuation allowances on U.S. federal and state deferred tax assets after reaching sustained profitability. The benefit was non-cash.

Demand, Customers and Pricing

Management’s commercial commentary was notably more measured than the headline revenue growth. Alnylam said the broader field-force expansion has increased healthcare-provider reach and engagement, but has not yet accelerated demand growth as anticipated.

The company attributed the slower conversion partly to the makeup of new target prescribers. Many have fewer ATTR-CM patients, less familiarity with the disease, and established prescribing habits. Management also pointed to practical adoption barriers, including buy-and-bill processes, prior authorizations, and coordinating treatment at sites of care outside physicians’ offices.

Alnylam believes these issues can be addressed through repeated engagement and patient-support services, but it does not expect material demand acceleration in Q4. That distinction matters: the commercial strategy may still work over time, but it has not yet demonstrated that it can rapidly convert untapped prescribers into incremental starts.

Access is another near-term uncertainty. UnitedHealth implemented a more restrictive first-line AMVUTTRA policy in the Medicare Advantage market on October 1. Management said existing patients should not be affected, and an exception process exists for appropriate new patients, but it expects the policy could create delays for new starts.

The potential revision to Medicare reimbursement for Part B medicines acquired through the 340B discount program is a larger issue. Alnylam described 340B exposure as meaningful but did not quantify it. If the proposed rule is finalized, health systems could continue buying through the 340B channel, shift to non-340B wholesale acquisition cost purchasing, or move patients to third-party infusion sites or home administration. Each path could affect net pricing, volume, and ordering patterns differently.

What is Alnylam’s guidance for FY 2026?

Alnylam reiterated its full-year 2026 guidance:

MetricFY 2026 Guidance
Total TTR net product revenue$4.2B to $4.5B
Total Rare net product revenue$500M to $600M
Total net product revenue$4.7B to $5.1B
Net product revenue growth at June 30, 2026 exchange rates57% to 71%
Net product revenue growth at constant exchange rates57% to 70%
Collaboration and royalty revenue$575M to $625M
Non-GAAP R&D and SG&A expense$2.7B to $2.8B

Management now expects full-year TTR revenue to land at the low end of the $4.2B to $4.5B range. It cited the slower-than-expected conversion of expanded commercial activity into demand, potential Q4 ordering volatility as health systems assess the pending 340B rule, and the UnitedHealth policy change.

Alnylam will not provide 2027 product-revenue guidance at the JPMorgan conference in January, as it has in prior years. Instead, management plans to issue 2027 guidance with Q4 and full-year results in February, allowing more time to assess provider behavior following any 340B reimbursement change.

On the pipeline, the company expanded enrollment in the Phase 3 TRITON-CM trial of nucresiran to approximately 2,250 patients from 1,750. Management said the increase is intended to preserve study power amid potentially lower event rates as ATTR-CM patients are diagnosed and treated earlier. It continues to expect a potential ATTR-CM launch around 2030, assuming positive data and regulatory approval.

Alnylam also plans to initiate a pivotal placebo-controlled trial of brezosiran in Huntington’s disease in 2027, pending regulatory alignment. Early Phase 1 data showed 60% to 64% mean reductions in cerebrospinal-fluid mutant huntingtin at the highest dose studied, with no dose-dependent safety signals reported to date.

Balance Sheet, Cash Flow and Capital

Cash, cash equivalents, and marketable securities reached $3.6B at September 30, up from $2.9B at year-end 2025. The increase was primarily driven by operating cash inflows and reflects the company’s transition to sustained profitability.

The balance sheet also includes meaningful financing-related obligations. Alnylam reported $1.0B of convertible debt, including $361.5M classified as current, along with $1.7B of liabilities related to the sale of future Leqvio royalties and development funding arrangements.

Interest expense was $84M in Q3. This included $58M associated with the liability related to sold future Leqvio royalties and $23M related to vutrisiran and zilebesiran development-funding liabilities. These costs should remain relevant when assessing cash generation beyond operating income.

What Investors Should Watch

1. AMVUTTRA demand excluding inventory and pricing effects

Q3 U.S. TTR growth included a $17M inventory benefit and approximately $10M in favorable one-time gross-to-net adjustments. Q4 performance will provide a cleaner test of underlying demand as management expects both factors to reverse.

2. Conversion of new prescribers into patient starts

Alnylam has expanded its commercial reach and added more than 2,000 AMVUTTRA prescribers, but the company said engagement has not yet produced the desired acceleration in demand. Growth in total prescriptions and broader use among community physicians will be important evidence that the investment is working.

3. 340B reimbursement and payer-access developments

The final 340B rule could affect health-system purchasing, site-of-care decisions, gross-to-net deductions, and potentially patient access. The UnitedHealth Medicare Advantage policy is a separate indication that payer controls may become more relevant as AMVUTTRA’s market expands.

4. TTR franchise durability beyond AMVUTTRA

The expanded TRITON-CM trial underscores the strategic importance of nucresiran to Alnylam’s long-term TTR position. The larger study is intended to protect statistical power, but it also reflects an evolving treatment environment with lower event rates that can make cardiovascular-outcomes studies more demanding.

5. Evidence that the pipeline can diversify revenue

Brezosiran’s early Huntington’s disease data are encouraging but remain preliminary and based on biomarker reduction and early safety observations. Investors should watch for regulatory alignment on the planned pivotal study and for upcoming data from ALN-6400 and ALN-2232.

AlgovestIQ Takeaway

Alnylam delivered another strong product-revenue quarter, and AMVUTTRA continues to establish itself as the company’s principal earnings engine. The TTR franchise generated $1.15B in quarterly revenue, while AMVUTTRA’s 65% growth demonstrates substantial adoption in ATTR-CM.

However, the quarter also exposed the difference between strong reported growth and the next commercial challenge. Some of Q3’s U.S. revenue benefited from inventory and favorable gross-to-net adjustments, while management acknowledged that its larger field force has not yet generated faster underlying patient demand. The company remains confident in its commercial approach, but the evidence needed now is sustained growth in starts that is not dependent on quarterly channel or pricing effects.

Access is the key near-term swing factor. A final 340B reimbursement rule, potential health-system response, and UnitedHealth’s more restrictive Medicare Advantage policy could affect the pace and economics of AMVUTTRA adoption. Management’s decision to delay 2027 guidance until February reflects the uncertainty around those variables.

Longer term, the investment case depends on whether Alnylam can extend its TTR leadership with nucresiran while developing meaningful non-TTR revenue platforms. The TRITON-CM enrollment expansion is designed to improve the probability of success without delaying the targeted 2030 launch window, but it also reinforces how important the program is to franchise durability. For now, the central question is whether AMVUTTRA’s sizable market opportunity can translate into faster, cleaner demand growth while Alnylam navigates a more complex access environment.

How did ALNY stock react?

ALNY closed at $174.00 on Oct 29, 2026, down 25.1% from $232.40 on Oct 28, 2026, the last close before the results were released.

SessionCloseChange
Oct 28, 2026 (before release)$232.40—
Oct 29, 2026$174.00-25.1%
Oct 30, 2026$165.00-29.0%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Alnylam Pharmaceuticals Q3 FY2026 earnings call transcript, as of Oct 29, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Alnylam Pharmaceuticals Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 29, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 29, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.